Regulatory

• 31 Oct, 2023
  Kommuniké från extra bolagsstämma i Spago Nanomedical AB den 31 oktober 2023
• 31 Oct, 2023
  Bulletin from the Extraordinary General Meeting of Spago Nanomedical AB on 31 October 2023
• 19 Oct, 2023
  Spago Nanomedical får klartecken att starta klinisk fas I/IIa-studie med Tumorad® i Australien
• 19 Oct, 2023
  Spago Nanomedical receives approval to initiate the clinical phase I/IIa study with Tumorad® in Australia
• 5 Oct, 2023
  Kallelse till extra bolagsstämma i Spago Nanomedical AB (publ)
• 5 Oct, 2023
  Notice to the Extraordinary General Meeting of Spago Nanomedical AB (publ)
• 5 Oct, 2023
  Spago Nanomedical föreslår en fullt garanterad företrädesemission av units om cirka 30,6 MSEK för att avancera Tumorad
• 5 Oct, 2023
  Spago Nanomedical proposes a fully guaranteed rights issue of units of approximately SEK 30.6 million to advance Tumorad
• 31 Jul, 2023
  Spago Nanomedical interim report January-June 2023
• 31 Jul, 2023
  Spago Nanomedical delårsrapport januari-juni 2023